Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection

Journal of Virology

Volumn 87, Issue 1, 2013, Pages 415-421

  Birlea, Marius ^a   Owens, Gregory P ^a   Eshleman, Emily M ^a   Ritchie, Alanna ^a   Traktinskiy, Igor ^a   Bos, Nathan ^a   Seitz, Scott ^a   Azarkh, Yevgeniy ^a   Mahalingam, Ravi ^a   Gilden, Don ^a   Cohrs, Randall J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN H; GLYCOPROTEIN L; HERPES ZOSTER IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; VIRUS GLYCOPROTEIN;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; EMBRYO; FLOW CYTOMETRY; HERPES ZOSTER; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOPRECIPITATION; MALE; MASS SPECTROMETRY; MEMBRANE FUSION; NONHUMAN; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TISSUE CULTURE; VIRUS ATTACHMENT; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOPRECIPITATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; VIRAL PROTEINS;

HUMAN HERPESVIRUS 3;

EID: 84872000832     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02561-12     Document Type: Article

References (38)

1. Rodriguez JE, Moninger T, Grose C. 1993. Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. Virology 196:840-844.
2. Vleck SE, Oliver SL, Reichelt M, Rajamani J, Zerboni L, Jones C, Zehnder J, Grose C, Arvin AM. 2010. Anti-glycoprotein H antibody impairs the pathogenicity of varicella-zoster virus in skin xenografts in the SCID mouse model. J. Virol. 84:141-152.
3. Vleck SE, Oliver SL, Brady JJ, Blau HM, Rajamani J, Sommer MH, Arvin AM. 2011. Structure-function analysis of varicella-zoster virus glycoprotein H identifies domain-specific roles for fusion and skin tropism. Proc. Natl. Acad. Sci. U. S. A. 108:18412-18417.
4. Zhang Z, Selariu A, Warden C, Huang G, Huang Y, Zaccheus O, Cheng T, Xia N, Zhu H. 2010. Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor. PLoS Pathog. 6:e1000971. doi:10.1371/ journal.ppat.1000971.
5. Cole NL, Grose C. 2003. Membrane fusion mediated by herpesvirus glycoproteins: the paradigm of varicella-zoster virus. Rev. Med. Virol. 13:207-222.
6. Dubey L, Steinberg SP, LaRussa P, Oh P, Gershon AA. 1988. Western blot analysis of antibody to varicella-zoster virus. J. Infect. Dis. 157:882-888.
7. Giller RH, Winistorfer S, Grose C. 1989. Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J. Infect. Dis. 160:919-928.
8. Haumont M, Jurdan M, Kangro H, Jacquet A, Massaer M, Deleersnyder V, Garcia L, Bosseloir A, Bruck C, Bollen A, Jacobs P. 1997. Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization. J. Med. Virol. 53:63-68.
9. Watson B, Gupta R, Randall T, Starr S. 1994. Persistence of cellmediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. J. Infect. Dis. 169:197-199.
10. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schodel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ. 2009. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J. Infect. Dis. 200:1068-1077.
11. Akahori Y, Suzuki K, Daikoku T, Iwai M, Yoshida Y, Asano Y, Kurosawa Y, Shiraki K. 2009. Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H. J. Virol. 83:2020-2024.
12. Arvin AM, Kinney-Thomas E, Shriver K, Grose C, Koropchak CM, Scranton E, Wittek AE, Diaz PS. 1986. Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J. Immunol. 137:1346-1351.
13. Grose C, Edwards DP, Friedrichs WE, Weigle KA, McGuire WL. 1983. Monoclonal antibodies against three major glycoproteins of varicellazoster virus. Infect. Immun. 40:381-388.
14. Montalvo EA, Grose C. 1987. Assembly and processing of the disulfidelinked varicella-zoster virus glycoprotein gpII(140). J. Virol. 61:2877-2884.
15. Sugano T, Tomiyama T, Matsumoto Y, Sasaki S, Kimura T, Forghani B, Masuho Y. 1991. A human monoclonal antibody against varicella-zoster virus glycoprotein III. J. Gen. Virol. 72:2065-2073.
16. Suzuki K, Akahori Y, Asano Y, Kurosawa Y, Shiraki K. 2007. Isolation of therapeutic human monoclonal antibodies for varicella-zoster virus and the effect of light chains on the neutralizing activity. J. Med. Virol. 79:852-862.
17. Forghani B, Ni L, Grose C. 1994. Neutralization epitope of the varicellazoster virus gH:gL glycoprotein complex. Virology 199:458-462.
18. Grose C, Carpenter JE, Jackson W, Duus KM. 2010. Overview of varicella- zoster virus glycoproteins gC, gH and gL. Curr. Top. Microbiol. Immunol. 342:113-128.
19. Maresova L, Kutinova L, Ludvikova V, Zak R, Mares M, Nemeckova S. 2000. Characterization of interaction of gH and gL glycoproteins of varicella- zoster virus: their processing and trafficking. J. Gen. Virol. 81:1545-1552.
20. Suenaga T, Satoh T, Somboonthum P, Kawaguchi Y, Mori Y, Arase H. 2010. Myelin-associated glycoprotein mediates membrane fusion and entry of neurotropic herpesviruses. Proc. Natl. Acad. Sci. U. S. A. 107:866-871.
21. Foung SK, Perkins S, Koropchak C, Fishwild DM, Wittek AE, Engleman EG, Grumet FC, Arvin AM. 1985. Human monoclonal antibodies neutralizing varicella-zoster virus. J. Infect. Dis. 152:280-285.
22. Kausmally L, Waalen K, Lobersli I, Hvattum E, Berntsen G, Michaelsen TE, Brekke OH. 2004. Neutralizing human antibodies to varicella-zoster virus (VZV) derived from a VZV patient recombinant antibody library. J. Gen. Virol. 85:3493-3500.
23. Lloyd-Evans P, Gilmour JE. 2000. Expression of neutralizing recombinant human antibodies against varicella zoster virus for use as a potential prophylactic. Hybridoma 19:143-149.
24. Sugano T, Matsumoto Y, Miyamoto C, Masuho Y. 1987. Hybridomas producing human monoclonal antibodies against varicella-zoster virus. Eur. J. Immunol. 17:359-364.
25. Marasco WA, Sui J. 2007. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol. 25:1421-1434.
26. Yokoyama T, Ayabe S, Miyagi H, Sugano T, Otsu A, Sato H, Kageyama S, Fujii T, Shiraki K. 2001. Varicella-zoster virus gH:gL contains a structure reactive with the anti-human gamma chain of IgG near the glycosylation site. J. Gen. Virol. 82:331-334.
27. Azarkh Y, Dolken L, Nagel M, Gilden D, Cohrs RJ. 2011. Synthesis and decay of varicella zoster virus transcripts. J. Neurovirol. 17:281-287.
28. Smith K, Garman L, Wrammert J, Zheng Capra N-YJD, Ahmed R, Wilson PC. 2009. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 4:372-384.
29. Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH. 2003. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J. Immunol. 171:2725-2733.
30. Owens GP, Bennett JL, Lassmann H, O'Connor KC, Ritchie AM, Shearer A, Lam C, Yu X, Birlea M, DuPree C, Williamson RA, Hafler DA, Burgoon MP, Gilden D. 2009. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann. Neurol. 65:639-649.
31. Mahalingam R, Wellish M, Cohrs R, Debrus S, Piette J, Rentier B, Gilden DH. 1996. Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc. Natl. Acad. Sci. U. S. A. 93:2122-2124.
32. Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, Mata S, Kremens D, Vitaliani R, Geschwind MD, Bataller L, Kalb RG, Davis R, Graus F, Lynch DR, Balice-Gordon R, Dalmau J. 2009. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann. Neurol. 65:424-434.
33. Davison AJ, Scott JE. 1986. The complete DNA sequence of varicellazoster virus. J. Gen. Virol. 67:1759-1816.
34. + T cells reconstituting during zoster after allogeneic transplantation. Haematologica 97:874-882.
35. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL. 2005. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352:2271-2284.
36. Shiraki K, Daikoku T, Takemoto M, Yoshida Y, Suzuki K, Akahori Y, Okuno T, Kurosawa Y, Asano Y. 2011. Neutralizing anti-gH antibody of varicella-zoster virus modulates distribution of gH and induces gene regulation, mimicking latency. J. Virol. 85:8172-8180.
37. Leoni V, Gianni T, Salvioli S, Campadelli-Fiume G. 2012. Herpes simplex virus glycoproteins gH/gL and gB bind Toll-like receptor 2, and soluble gH/gL is sufficient to activate NF-kappaB. J. Virol. 86: 6555-6562.
38. Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B. 2012. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J. Virol. 86:7444-7447.